Silence raises £19 million in stock placing
This article was originally published in Scrip
Executive Summary
Silence Therapeutics has raised £19 million to support its RNAi portfolio through a placing of 9.5 million shares, cashing in on a renewed focus on RNAi companies following AstraZeneca's recent decision to invest $240million into small RNAi focused biotech Moderna Therapeutics.